iliac stenting
DeviceAbsolute Pro (Abbott Vascular) or Omnilink Elite (Abbott Vascular) stents
NCT Number: NCT00764777
The BRAVISSIMO trial wants to investigate in a controlled setting, the long-term (up to 24 months) outcome of the self-expanding nitinol Absolute Pro (Abbott Vascular) and the balloon-expandable Omnilink Elite (Abbott Vascular) stent in TASC A&B and TASC C&D iliac lesions. A separate analysis of both patient populations will be performed and listed.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Universitair Ziekenhuis Antwerpen, Antwerp, Belgium
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
GENERAL
ANGIOGRAPHIC
Exclusion criteria
Absolute Pro (Abbott Vascular) or Omnilink Elite (Abbott Vascular) stents
Time frame: 12 months
Time frame: Procedure
Time frame: 1, 6 & 24 months
Time frame: 1, 6, 12 & 24 months
Time frame: 1, 6, 12, 24 months
Flanders Medical Research Program
Network
Physician Initiated Multi-center Belgian-Italian-Dutch Trial Investigating Abbott Vascular Iliac Stents in the Treatment of TASC A, B, C & D Iliac Lesions
Acronym: BRAVISSIMO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00637741
Arterial Occlusive Diseases, Arteriosclerosis
Bonheiden, Belgium
View Trial DetailsNCT02823444
Arterial Occlusive Diseases, Arteriosclerosis
Salt Lake City, Utah, United States
View Trial DetailsNCT02786173
Arterial Occlusive Diseases, Arteriosclerosis
Orlando, Florida, United States
View Trial DetailsNCT03511157
Arterial Occlusive Diseases, Arteriosclerosis
Milwaukee, Wisconsin, United States
View Trial Details